Drug Trial Radar · NCT00596791
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
Last checked: Nov 20, 2026Latest source record: Jan 12, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 2008
Primary completion
Jul 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- Santen OyIndustry
- Sponsor type
- Industry
- First posted
- Jan 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.
Conditions
- Ocular Hypertension
- Open-Angle Glaucoma
Interventions
tafluprostDrug
prostaglandine analoque
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from screening in ocular symptoms and signsTime frame: at week 6 and 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Finn-Medi Research Oy
Tampere, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.